The president of the Cuban company BioCubaFarma, Eduardo Martínez, provided this Friday data on the effectiveness of the immunization of the local population against covid-19 with the vaccines developed by the island’s scientists.
According to Martínez, until August 10 one can speak of a “remarkable impact” in Havana, especially in the first four municipalities to complete the complete immunization process, that is, where residents received the three doses and accumulated 14 days or more after receiving the last one.
Thus, of the 2.5 million people who completely completed the immunization process, “only” 21,000, or 0.8%, contracted the coronavirus. Of these, 99 people died, which represents 0.003%. “It really is very encouraging data”, Martínez pointed out, aforementioned through the Caribbean Channel.
In addition, in relation to the delta variant of the virus, which is also present in Cuba, the president of BioCubaFarma assured that “there is important evidence that vaccines in general, and Cuban vaccines, are protecting, above all, from severe systemic disease“.
Martínez reported that more than 14 million doses of vaccines have already been delivered to the country’s public health systems and that “very soon” the number of manufactured doses will reach 20 million. “Between the months of August and September we must complete the amount of vaccines that are needed to immunize our population,” he said.
So far, Cuba has five anticovid drugs under investigation: Soberana 01, Soberana 02, Soberana Plus, Abdala and Mambisa, plus a sixth in a joint study with Chinese scientists, called Pan-Corona. On July 9, the island’s health authority authorized the emergency use of Abdala, which, together with Cuba’s other most advanced vaccine, Soberana 02, is administered en masse to the Cuban population.